BSD Medical's BSD-2000 extends survival by 32% in pancreatic cancer trial

By Elaine Rigoli

Tampa, Fla., July 19 - BSD Medical Corp. announced that phase 2 research conducted in Munich, Germany, with the BSD-2000 cancer therapy system demonstrated improvement in patients with pancreatic cancer, even in the worst stage of the disease.

When 12 patients with advanced or metastatic pancreatic cancer who had already failed in the current first line treatment with chemotherapy were given chemotherapy in conjunction with hyperthermia therapy provided by the BSD-2000 as a second-line therapy, the one-year event-free survival rate was 32%.

For advanced or metastatic pancreatic cancer patients receiving the current standard care (chemotherapy using gemcitabine), results vary. The company said an 18% survival at one year appears to be what can be expected.

BSD Medical, based in Salt Lake City, produces precision-guided radiofrequency and microwave heat therapy systems used in the treatment of cancer and other diseases or medical conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.